TY - JOUR
T1 - Interleukin-17 in transverse myelitis and multiple sclerosis
AU - Graber, Jerome J.
AU - Allie, S. Rameeza
AU - Mullen, Katherine M.
AU - Jones, Melina
AU - Wang, Tongguang
AU - Krishnan, Chitra
AU - Kaplin, Adam I
AU - Nath, Avindra
AU - Kerr, Douglas A.
AU - Calabresi, Peter A.
PY - 2008/5/30
Y1 - 2008/5/30
N2 - CSF IL-6 is elevated in transverse myelitis (TM) and predicts disability. Since IL-17 regulates cytokines (TNFα, IL-1β and IL-6) known to stimulate IL-6 production by astrocytes, we sought to determine whether IL-17 was increased in TM and MS compared to healthy controls (HC) and other neurologic diseases (OND). IL-17 and IL-6 levels were measured in stimulated peripheral blood mononuclear cell (PBMC) supernatants from HC, MS, TM and OND. IL-17 was increased in TM compared to HC, MS, and OND (mean pg/ml ± standard error; HC: 36.1 ± 11.7, MS: 89.4 ± 23.3, TM: 302.6 ± 152.5, OND: 41.2 ± 13.0, p = 0.01). IL-6 was increased in TM relative to MS and HC (HC: 2624 pg/ml ± 641, MS: 6129 ± 982, TM: 12,536 ± 2657, OND: 6920 ± 1801, p < 0.002). MS patients with early disease (< 2 years) also had increased levels of IL-17 (p < 0.04) and IL-6 (p < 0.05). Cytokine neutralization experiments demonstrated that IL-6 was the main inducer of astrocyte IL-6 production. We conclude that IL-17 and IL-6 production from PBMC in TM and early MS are increased and induce astrocyte IL-6 production through IL-6.
AB - CSF IL-6 is elevated in transverse myelitis (TM) and predicts disability. Since IL-17 regulates cytokines (TNFα, IL-1β and IL-6) known to stimulate IL-6 production by astrocytes, we sought to determine whether IL-17 was increased in TM and MS compared to healthy controls (HC) and other neurologic diseases (OND). IL-17 and IL-6 levels were measured in stimulated peripheral blood mononuclear cell (PBMC) supernatants from HC, MS, TM and OND. IL-17 was increased in TM compared to HC, MS, and OND (mean pg/ml ± standard error; HC: 36.1 ± 11.7, MS: 89.4 ± 23.3, TM: 302.6 ± 152.5, OND: 41.2 ± 13.0, p = 0.01). IL-6 was increased in TM relative to MS and HC (HC: 2624 pg/ml ± 641, MS: 6129 ± 982, TM: 12,536 ± 2657, OND: 6920 ± 1801, p < 0.002). MS patients with early disease (< 2 years) also had increased levels of IL-17 (p < 0.04) and IL-6 (p < 0.05). Cytokine neutralization experiments demonstrated that IL-6 was the main inducer of astrocyte IL-6 production. We conclude that IL-17 and IL-6 production from PBMC in TM and early MS are increased and induce astrocyte IL-6 production through IL-6.
KW - Astrocytes
KW - Interleukin 17
KW - Interleukin 6
KW - Multiple sclerosis
KW - T cells
KW - Transverse myelitis
UR - http://www.scopus.com/inward/record.url?scp=44349141220&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44349141220&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2008.02.008
DO - 10.1016/j.jneuroim.2008.02.008
M3 - Article
C2 - 18417225
AN - SCOPUS:44349141220
SN - 0165-5728
VL - 196
SP - 124
EP - 132
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
IS - 1-2
ER -